Emerging Science (Late-Breaker Equivalent) Abstract To Be Presented At 5:30PM Local Time Highlights Phase 2 PARADIGM Outcomes CAMBRIDGE, Mass., April 12, 2024 /PRNewswire/ -- NeuroSense...

- Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine - Seventy percent of...

Eisai Inc. announced today the Company will present findings from its robust neurology portfolio, including data from the Phase 3 Clarity AD trial for LEQEMBI® (lecanemab-irmb), Eisai's...

The First Wave of All-Star Speakers has been Announced for Europe's Leading Festival of AI and Transformational Technology, Which is now Taking Place for the First Time in the U.S. LOS ANGELES,...

The international cinema industry conference, CinemaCon 2024 was held from April 9 to 11 at Caesars Palace, Las Vegas. As the largest and most important gathering for the worldwide motion picture...

Prophylactic administration of a selective COX-2 inhibitor reduces the volume of edema associated with photoimmunotherapy by 30-50% Reduced edema volume by 25%, even when administered post...

Russian River Valley Wine Weekend to Include Three Days of New Experiences August 2nd – 4th, 2024 SANTA ROSA, Calif., April 11, 2024 /PRNewswire/ -- In celebration of the 10th Anniversary the...

Rivergate Marketing's Vice President of Account Services Christine McQuilkin and Digital Marketing Account Manager Grace Clark will present 'How to Create Compelling Technical Content and Track...

Poster #14-006 describes the first successful treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR-T cells Kyverna to host a...

Numerous enhancements to the guest experience in store for Clear Sky Resorts Grand Canyon visitors during the 2024 season PHOENIX, April 11, 2024 /PRNewswire/ -- Clear Sky Resorts announces an...